Evaluation of Comparative Surveillance Strategies of Circulating Tumor DNA, Imaging, and Carcinoembryonic Antigen Levels in Patients With Resected Colorectal Cancer
Sign Up to like & getrecommendations! Published in 2022 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2022.1093
Abstract: Key Points Question Is serial analysis of circulating tumor DNA (ctDNA) associated with improved sensitivity and earlier detection of recurrence compared with standard imaging and evaluation of carcinoembryonic antigen (CEA) levels per National Comprehensive Cancer… read more here.
Keywords: circulating tumor; resected colorectal; colorectal cancer; tumor dna ... See more keywords
Circulating Tumor DNA and Survival in Metastatic Breast Cancer
Sign Up to like & getrecommendations! Published in 2024 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2024.31722
Abstract: Key Points Question What is the association between detection of specific alterations in circulating tumor DNA (ctDNA) and survival in patients with metastatic breast cancer? Findings In this systematic review and meta-analysis reporting data from… read more here.
Keywords: breast cancer; circulating tumor; survival; metastatic breast ... See more keywords
Circulating Tumor Cell Count and Overall Survival in Patients With Metastatic Hormone-Sensitive Prostate Cancer
Sign Up to like & getrecommendations! Published in 2024 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2024.37871
Abstract: Key Points Question Is circulating tumor cell (CTC) count at the start of treatment associated with overall survival in metastatic hormone-sensitive prostate cancer (mHSPC)? Findings In this prognostic study of 1313 men initiating systemic hormonal… read more here.
Keywords: tumor cell; survival; metastatic hormone; count ... See more keywords
Circulating Tumor DNA as Measurable Residual Disease in Aggressive B-Cell Lymphoma: A Narrative Review.
Sign Up to like & getrecommendations! Published in 2025 at "JAMA oncology"
DOI: 10.1001/jamaoncol.2024.6144
Abstract: Importance Achieving remission is the first step toward a cure in treating aggressive B-cell lymphomas. Radiographic imaging, such as fluorodeoxyglucose-positron emission tomography/computed tomography scans are the current standard to define remission at the end of… read more here.
Keywords: disease; tumor; circulating tumor; cell ... See more keywords
Characterization of single circulating tumor cells
Sign Up to like & getrecommendations! Published in 2017 at "FEBS Letters"
DOI: 10.1002/1873-3468.12662
Abstract: “Liquid biopsy” has been introduced for the analysis of circulating tumor cells (CTCs) in the blood of cancer patients, and this new diagnostic approach has received enormous attention. CTCs are derived from primary tumors and… read more here.
Keywords: tumor cells; single circulating; circulating tumor; characterization single ... See more keywords
High‐throughput isolation of circulating tumor DNA: a comparison of automated platforms
Sign Up to like & getrecommendations! Published in 2019 at "Molecular Oncology"
DOI: 10.1002/1878-0261.12415
Abstract: The emerging interest in circulating tumor DNA (ctDNA) analyses for clinical trials has necessitated the development of a high‐throughput method for fast, reproducible, and efficient isolation of ctDNA. Currently, the majority of ctDNA studies use… read more here.
Keywords: dna; circulating tumor; isolation; tumor dna ... See more keywords
AR splice variants in circulating tumor cells of patients with castration‐resistant prostate cancer: relation with outcome to cabazitaxel
Sign Up to like & getrecommendations! Published in 2019 at "Molecular Oncology"
DOI: 10.1002/1878-0261.12529
Abstract: The androgen receptor splice variant (AR‐V) 7 in circulating tumor cells (CTCs) is a predictor for resistance to anti‐AR‐targeted treatment, but not to taxane‐based chemotherapy in metastatic castration‐resistant prostate cancer (mCRPC). In this study, we… read more here.
Keywords: prostate; tumor cells; prostate cancer; circulating tumor ... See more keywords
Clinical utility of circulating tumor cells: an update
Sign Up to like & getrecommendations! Published in 2020 at "Molecular Oncology"
DOI: 10.1002/1878-0261.12869
Abstract: The prognostic role of circulating tumor cells (CTCs) has been clearly demonstrated in many types of cancer. However, their roles in diagnostic and treatment strategies remain to be defined. In this review, we present an… read more here.
Keywords: utility circulating; clinical utility; utility; tumor cells ... See more keywords
Early circulating tumor DNA dynamics as a pan‐tumor biomarker for long‐term clinical outcome in patients treated with durvalumab and tremelimumab
Sign Up to like & getrecommendations! Published in 2022 at "Molecular Oncology"
DOI: 10.1002/1878-0261.13349
Abstract: There is an urgent need to identify biomarkers of early response that can accurately predict the benefit of immune checkpoint inhibitors (ICI). Patients receiving durvalumab/tremelimumab had tumor samples sequenced before treatment (baseline) to identify variants… read more here.
Keywords: circulating tumor; biomarker; tumor; treatment ... See more keywords
Circulating tumor cells in metastatic breast cancer patients treated with immune checkpoint inhibitors – a biomarker analysis of the ALICE and ICON trials
Sign Up to like & getrecommendations! Published in 2024 at "Molecular Oncology"
DOI: 10.1002/1878-0261.13675
Abstract: Immune checkpoint inhibitors (ICIs) have been introduced in breast cancer (BC) treatment and better biomarkers are needed to predict benefit. Circulating tumor cells (CTCs) are prognostic in BC, but knowledge is limited on CTCs in… read more here.
Keywords: breast cancer; immune checkpoint; tumor cells; tumor ... See more keywords
Detection rate for ESR1 mutations is higher in circulating‐tumor‐cell‐derived genomic DNA than in paired plasma cell‐free DNA samples as revealed by ddPCR
Sign Up to like & getrecommendations! Published in 2025 at "Molecular Oncology"
DOI: 10.1002/1878-0261.13787
Abstract: Plasma cell‐free DNA (cfDNA) analysis to track estrogen receptor 1 (ESR1) mutations is highly beneficial for the identification of tumor molecular dynamics and the improvement of personalized treatments for patients with metastatic breast cancer (MBC).… read more here.
Keywords: cell; circulating tumor; ctc derived; esr1 mutations ... See more keywords